Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

In the last 30 years, there have been many advances in the treatment of metastatic renal cell carcinoma of the clear cell type. Renal cell carcinoma has long been understood to have a component of immune mediation and has been responsive to immune-based therapies; in addition to early cytokine therapy, newer checkpoint inhibition therapies have also demonstrated activity. Molecular characterization of the genome of clear cell renal cell carcinoma enabled identification of the roles of angiogenesis and hypoxic stress. This led to development of small-molecule tyrosine kinase inhibitors and inhibitors of mammalian target of rapamycin that have provided additional benefit to patients. Ongoing strategies of combinations of immune and antiangiogenic therapies may lead to further advancements.

Original languageEnglish (US)
Pages (from-to)209-221
Number of pages13
JournalAnnual Review of Medicine
Volume69
DOIs
StatePublished - Jan 29 2018

Fingerprint

Cells
Renal Cell Carcinoma
Sirolimus
Protein-Tyrosine Kinases
Therapeutics
Secondary Prevention
Genes
Cytokines
Molecules
Genome
Clear-cell metastatic renal cell carcinoma

Keywords

  • Angiogenesis
  • Checkpoint inhibitor
  • Immunotherapy
  • MTOR

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type. / Parikh, Mamta; Lara, Primo N.

In: Annual Review of Medicine, Vol. 69, 29.01.2018, p. 209-221.

Research output: Contribution to journalReview article

@article{dbe6e2f58db74acc97d68aad29ac5d10,
title = "Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type",
abstract = "In the last 30 years, there have been many advances in the treatment of metastatic renal cell carcinoma of the clear cell type. Renal cell carcinoma has long been understood to have a component of immune mediation and has been responsive to immune-based therapies; in addition to early cytokine therapy, newer checkpoint inhibition therapies have also demonstrated activity. Molecular characterization of the genome of clear cell renal cell carcinoma enabled identification of the roles of angiogenesis and hypoxic stress. This led to development of small-molecule tyrosine kinase inhibitors and inhibitors of mammalian target of rapamycin that have provided additional benefit to patients. Ongoing strategies of combinations of immune and antiangiogenic therapies may lead to further advancements.",
keywords = "Angiogenesis, Checkpoint inhibitor, Immunotherapy, MTOR",
author = "Mamta Parikh and Lara, {Primo N}",
year = "2018",
month = "1",
day = "29",
doi = "10.1146/annurev-med-041916-124132",
language = "English (US)",
volume = "69",
pages = "209--221",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type

AU - Parikh, Mamta

AU - Lara, Primo N

PY - 2018/1/29

Y1 - 2018/1/29

N2 - In the last 30 years, there have been many advances in the treatment of metastatic renal cell carcinoma of the clear cell type. Renal cell carcinoma has long been understood to have a component of immune mediation and has been responsive to immune-based therapies; in addition to early cytokine therapy, newer checkpoint inhibition therapies have also demonstrated activity. Molecular characterization of the genome of clear cell renal cell carcinoma enabled identification of the roles of angiogenesis and hypoxic stress. This led to development of small-molecule tyrosine kinase inhibitors and inhibitors of mammalian target of rapamycin that have provided additional benefit to patients. Ongoing strategies of combinations of immune and antiangiogenic therapies may lead to further advancements.

AB - In the last 30 years, there have been many advances in the treatment of metastatic renal cell carcinoma of the clear cell type. Renal cell carcinoma has long been understood to have a component of immune mediation and has been responsive to immune-based therapies; in addition to early cytokine therapy, newer checkpoint inhibition therapies have also demonstrated activity. Molecular characterization of the genome of clear cell renal cell carcinoma enabled identification of the roles of angiogenesis and hypoxic stress. This led to development of small-molecule tyrosine kinase inhibitors and inhibitors of mammalian target of rapamycin that have provided additional benefit to patients. Ongoing strategies of combinations of immune and antiangiogenic therapies may lead to further advancements.

KW - Angiogenesis

KW - Checkpoint inhibitor

KW - Immunotherapy

KW - MTOR

UR - http://www.scopus.com/inward/record.url?scp=85041731001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041731001&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-041916-124132

DO - 10.1146/annurev-med-041916-124132

M3 - Review article

C2 - 29144835

AN - SCOPUS:85041731001

VL - 69

SP - 209

EP - 221

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -